The Frequency of Optimal Glycemic Control After Adding Sitagliptin onTreatment Regimen of Patient With Type 2 Diabetic

Dipeptidyl peptidase-4 inhibitors (DPP4-I) including sitagliptin is a new therapeuticclass of oral anti-hyperglycemic drugs for T2DM. The aim of this study was to evaluate the frequencyof glycemic control after adding sitagliptin on treatment regimen of patient with type 2 diabetic.

This cross-sectional study conducted on 120 patients with type 2 diabetes mellitusreferring to diabetes clinic of Imam Hospital, Ahvaz in 2019-2020. Sitagliptin (100 mg/day) was added tothe preexisting therapy for type 2 diabetes (metformin / metformin + gliclazide / metformin + insulin).Therapeutic effects and glycemic control (Changes in the glycated hemoglobin (HbA1c) level) after 3months of treatment were compared with the baseline.

The result of this study showed that after 3 months of treatment the level of FBS, BS-2h andHbA1C in 3 groups were significantly reduced compared with before treatment (P<0.0001), but the patientsweight in the three groups were not significantly changed (P=0.568). There was no significantdifference in the frequency of glycemic control between the patients treated with different concomitantdrugs (P=0.501). The results revealed that patients younger age (P=0.041), shorter disease duration(P=0.021) and with higher HbA1c levels at baseline (P<0.0001) were likely to show more decreased inHbA1c levels.

Our study shows that sitagliptin (in combination with different type of treatment regimens)has the potential to improve glycemic control and prevent hypoglycemia and weight gain, and can beconsidered a useful drug in patients with type 2 diabetes mellitus.